Next Article in Journal
Changes in Lipidomics, Metabolomics, and the Gut Microbiota in CDAA-Induced NAFLD Mice after Polyene Phosphatidylcholine Treatment
Next Article in Special Issue
Immunopharmacological Activities of Luteolin in Chronic Diseases
Previous Article in Journal
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study
Previous Article in Special Issue
β-Caryophyllene Acts as a Ferroptosis Inhibitor to Ameliorate Experimental Colitis
 
 
Review
Peer-Review Record

Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer

Int. J. Mol. Sci. 2023, 24(2), 1498; https://doi.org/10.3390/ijms24021498
by Ji Hye Yoon 1, Mi-Yeon Kim 2,* and Jae Youl Cho 1,3,*
Reviewer 1:
Reviewer 2:
Int. J. Mol. Sci. 2023, 24(2), 1498; https://doi.org/10.3390/ijms24021498
Submission received: 25 December 2022 / Revised: 8 January 2023 / Accepted: 10 January 2023 / Published: 12 January 2023

Round 1

Reviewer 1 Report

My main comments:

1/ keywords cannot duplicate with the title

2/ names of chapters and subchapters should be capitalized

3/ on the structural formula, please mark individual rings in the flavonoid skeleton and number the carbon atoms

4/ "in vitro", "in vivo", etc. please write in italics

5/ please adapt the method of citation to IJMS requirements - especially citations where the names of given authors appear in the text

6/ in the names of chemical compounds, the oxygen atom "O" must be written in italics

7/ for the drawings/graphics used, the source should be given

8/ Figure 9. please adjust the font to match the one used throughout the text

9/ please provide DOI numbers in the References section

10/ please provide confirmation of the linguistic correction of the text

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

1. Figure 9 content is very poor. it must be redrawn. 

2. application of apigenin in different skin disease must be more elaborated. 

3. Dose of apigenin for different skin disease must be reported.

4. A summarized and comprehensive table must be added for the apigenin application in different disese.

5. Is there any marketed product of apigenin reported. 

6. Figure resolution must be improved.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Accept in present form.

Reviewer 2 Report

Accept

Back to TopTop